Back to search

Article

Estimated absolute benefit of adjuvant endocrine therapy after partial-breast irradiation in hormone receptor-positive early breast cancer: a calibrated competing-risks scenario analysis of randomized-trial data

2026-08-25

Abstract excerpt

<title>Abstract</title> <p>Background Early breast cancer is being de-escalated on two fronts: partial-breast irradiation (PBI) or radiotherapy omission, and shorter or omitted endocrine therapy (ET). The pivotal PBI trials permitted but did not randomise ET, and omission trials held ET fixed, so ET’s incremental benefit on a PBI background is unknown. Methods We built a calibrated cause-specific competing-risk...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c6a13a34-1e9a-5ec8-b43e-64330f08c10c
DOI
10.21203/rs.3.rs-10594490/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Estimated absolute benefit of adjuvant endocrine therapy after partial-breast irradiation in hormone receptor-positive early breast cancer: a calibrated competing-risks scenario analysis of randomized-trial dataDOI 10.21203/rs.3.rs-10594490/v1
Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.Semantic proximity
Neoadjuvant immune-modulating SBRT and anti-CD73 to increase response to anti-PD-L1 and chemotherapy in early ER+/HER2- breast cancer: primary endpoint and translational results from the randomized Neo-CheckRay trialSemantic proximity
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.Semantic proximity
GARD is a pan-cancer predictor of radiation therapy benefitSemantic proximity
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.Semantic proximity
Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial.Semantic proximity
Efficacy and Safety of Post-CDK4/6 Inhibitor Treatment Options for HR-Positive, HER2-Negative Advanced Breast Cancer: A Network Meta-Analysis of Randomized Controlled TrialsSemantic proximity
The Value of Oral Selective Estrogen Receptor Degraders in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer after Progression on ≥ 1 Line of Endocrine Therapy: Systematic Review and Meta-analysisSemantic proximity
Biologically-based mechanistic models of radiation-related carcinogenesis applied to epidemiological dataSemantic proximity
Incidence and temporal patterns of true recurrences and second primaries in women with breast cancer: a 10-year competing risk-adjusted analysisSemantic proximity
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?Semantic proximity
Toxicity of External Beam Accelerated Partial-Breast Irradiation (APBI) in Adjuvant Therapy of Early-stage Breast Cancer: Randomized Prospective StudySemantic proximity
Select a neighboring publication to make it the new centre.